Amyotrophic Lateral Sclerosis

Rethinking anti-protein therapies for neurodegenerative diseases 2:29
Rethinking anti-protein therapies for neurodegenerative diseases
Alberto Espay • 27 Apr 2023
Putting the MND community at the heart of MND Scotland’s research strategy 3:23
Putting the MND community at the heart of MND Scotland’s research strategy
Jane Haley • 24 Apr 2023
MND-SMART: the adaptive platform trial investigating potential treatments for MND 3:22
MND-SMART: the adaptive platform trial investigating potential treatments for MND
Jane Haley • 24 Apr 2023
The MND Scotland strategy: making time count 2:18
The MND Scotland strategy: making time count
Jane Haley • 24 Apr 2023
Developing antibodies against pathogenic TDP-43 in ALS 3:42
Developing antibodies against pathogenic TDP-43 in ALS
Johanne Kaplan • 30 Mar 2023
Key findings from Phase IIa study of PrimeC in ALS patients 3:07
Key findings from Phase IIa study of PrimeC in ALS patients
Shiran Salomon-Zimri • 27 Mar 2023
Novel combination therapy PrimeC in ALS: biomarker data & launch of Phase II trial 10:55
Novel combination therapy PrimeC in ALS: biomarker data & launch of Phase II trial
Shiran Salomon-Zimri • 27 Mar 2023
The significance of glial cells in the pathophysiology of ALS 3:23
The significance of glial cells in the pathophysiology of ALS
Serge Przedborski • 16 Sep 2022
Pridopidine application beyond Huntington’s disease 3:03
Pridopidine application beyond Huntington’s disease
Michael Hayden • 27 Sep 2022
Phase II extension trial of CNM-Au8 in ALS 1:51
Phase II extension trial of CNM-Au8 in ALS
Matthew Kiernan • 4 Apr 2022
The pipeline of late-stage therapeutic options for patients with ALS 1:49
The pipeline of late-stage therapeutic options for patients with ALS
Matthew Kiernan • 4 Apr 2022
An overview of the developments in ALS research 1:15
An overview of the developments in ALS research
Matthew Kiernan • 4 Apr 2022
Important developments in understanding the mechanisms of ALS 1:47
Important developments in understanding the mechanisms of ALS
Matthew Kiernan • 4 Apr 2022
Personalizing therapy: the future of ALS treatment 1:48
Personalizing therapy: the future of ALS treatment
Nigel Leigh • 17 Mar 2022
Developing biomarker panels for ALS diagnosis 2:53
Developing biomarker panels for ALS diagnosis
Nigel Leigh • 17 Mar 2022
Changing our approach to ALS clinical trial design 3:44
Changing our approach to ALS clinical trial design
Nigel Leigh • 17 Mar 2022
The content of VJNeurology is intended for healthcare professionals